ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

By afschroeder • July 10, 2026

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan A, Puig-Lombardi ME, Fox J, Kirma J, Zhang H, Gu Y, Bogle R, Boniface K, Seneschal J, Seabra L, Lepelley A, Frémond ML, Bondurand N, Jouanguy E, Modlin RL, Casanova JL, Di Domizio J, Gilliet M, Sbidian E, Battistella M, Mahé E, Guégan S, Tsoi LC, Richette P, Claudepierre P, Rigolet A, Giannesini C, Costanzo A, Duffy D, Rosenberg BR, Sathishkumar D, Bourrat E, Chang CH, Hovnanian A, Gudjonsson JE, Crow YJ, Bachelez H. ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype. J Exp Med. 2026 Sep 7;223(9):e20260054. doi: 10.1084/jem.20260054. Epub 2026 Jul 9. PMID: 42424135.

Tags: Dermatology, Publications

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease[...]